Prevention of β Thalassemia in Northern Israel - a Cost-Benefit Analysis

BACKGROUND: β Thalassemia major is characterized by hemolytic anemia, ineffective erythropoiesis and hemosiderosis. About 4% of the world population carries a Thalassemia gene. Management includes blood transfusions and iron chelation. However, this treatment is costly, and population screening may...

Descripción completa

Detalles Bibliográficos
Autores principales: Koren, Ariel, Profeta, Lora, Zalman, Luci, Palmor, Haya, Levin, Carina, Zamir, Ronit Bril, Shalev, Stavit, Blondheim, Orna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965716/
https://www.ncbi.nlm.nih.gov/pubmed/24678389
http://dx.doi.org/10.4084/MJHID.2014.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965716/
https://www.ncbi.nlm.nih.gov/pubmed/24678389
http://dx.doi.org/10.4084/MJHID.2014.012

Ejemplares similares